Efficacy and Safety of Prurisol Administered Orally for Active Moderate to Severe Chronic Plaque Psoriasis
Status:
Completed
Trial end date:
2017-12-01
Target enrollment:
Participant gender:
Summary
This study is designed as a randomized, double blind, parallel group, placebo-controlled
trial to study the efficacy and safety of two oral doses of Prurisol administered twice daily
for twelve weeks to subjects with moderate to severe chronic plaque psoriasis.
Phase:
Phase 2
Details
Lead Sponsor:
Cellceutix Corporation Innovation Pharmaceuticals, Inc.